MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/hc9.0000000000000827

Медицинская библиотека · Hepatology communications · 2025

Denosumab versus zoledronic acid for osteoporosis treatment in patients with primary biliary cholangitis (the DELTA Study): A multicenter, non-inferiority randomized trial.

Arase Yoshitaka, Okubo Tomomi, Arai Taeang, Abe Masanori, Namisaki Tadashi, Uojima Haruki, Matsumoto Kosuke, Kakisaka Keisuke, Setsu Toru, Mishima Yusuke, Tsuruya Kota, Hirose Shunji, Deguchi Ryuzo, Shiraishi Koichi, Atsukawa Masanori, Ikegami Tadashi, Honda Akira, Terai Shuji, Yoshiji Hitoshi, Komori Atsumasa, Tanaka Atsushi, Kagawa Tatehiro

СтатьяМногоцентровое исследованиеРандомизированное исследованиеСравнительное исследованиеEquivalence TrialПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

Osteoporosis is a common complication in patients with primary biliary cholangitis (PBC). This study aimed to compare the efficacy and safety of denosumab and zoledronic acid (ZOL) in treating osteoporosis in PBC patients.

METHODS

This multicenter, randomized, open-label trial enrolled Japanese patients with PBC and osteoporosis. Patients were randomized to receive either subcutaneous denosumab 60 mg every 6 months (denosumab group) or i.v. zoledronic acid 5 mg yearly (ZOL group). The primary endpoint was the mean percent change in bone mineral density (BMD) at the lumbar spine and total hip from baseline to 12 months.

RESULTS

Of 47 enrolled patients, 41 (87.2%) completed the study (denosumab: n=21; ZOL: n=20). At 12 months, lumbar spine BMD increased by 7.5% in the denosumab group and 6.4% in the ZOL group, demonstrating the non-inferiority of denosumab (95% CI: -1.6% to 3.8%). Although the total hip BMD increased more in the denosumab group than in the ZOL group (5.0% vs. 2.6%, p<0.01), the difference did not meet the predefined non-inferiority margin (95% CI: -1.3% to 6.2%). Serum ALP to upper limit of normal ratio and bone turnover markers significantly decreased in both groups; however, the rates of change were not significantly different between them. The incidence of adverse events was significantly lower in the denosumab group compared with the ZOL group (14.3% vs. 50.0%, p=0.013).

CONCLUSIONS

Denosumab is a safe and effective treatment option for osteoporosis in patients with PBC.

Для цитирования: Arase Yoshitaka, Okubo Tomomi, Arai Taeang, Abe Masanori, Namisaki Tadashi, Uojima Haruki, Matsumoto Kosuke, Kakisaka Keisuke, Setsu Toru, Mishima Yusuke, Tsuruya Kota, Hirose Shunji, Deguchi Ryuzo, Shiraishi Koichi, Atsukawa Masanori, Ikegami Tadashi, Honda Akira, Terai Shuji, Yoshiji Hitoshi, Komori Atsumasa, Tanaka Atsushi, Kagawa Tatehiro. Denosumab versus zoledronic acid for osteoporosis treatment in patients with primary biliary cholangitis (the DELTA Study): A multicenter, non-inferiority randomized trial.. Hepatology communications. 2025. DOI: 10.1097/hc9.0000000000000827.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.